Octapharma IGIV Octagam Approved
This article was originally published in The Pink Sheet Daily
Octapharma's IGIV product Octagam will be available in mid-June following FDA approval May 21
You may also be interested in...
Promotional materials disseminated by Octapharma at an American Academy of Allergy, Asthma & Immunology meeting also failed to reveal risks associated with use of the intravenous immune globulin.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.